Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mouth Neoplasms 1Lymphedema 1HIV Infections 1Fallopian Tube Neoplasms 1Eyelid Sebaceous Gland Carcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Anus Neoplasms 1

Interventions

Doxorubicin 8Vincristine 7Etoposide 7Cyclophosphamide 7Rituximab 5Prednisone 5Filgrastim 5Zidovudine 3Bleomycin 3Vinblastine 2Thalidomide 2Paclitaxel 2Mitoxantrone 2Interferon-alpha 2Interferon alpha-2 2Dacarbazine 2Cytarabine 2Cisplatin 2ziconotide 1vesnarinone 1tin etiopurpurin 1nirogacestat 1liposomal doxorubicin 1interferon gamma-1b 1fludarabine phosphate 1fludarabine 1efavirenz 1dehydroftorafur 1Whole-Body Irradiation 1Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HIV Infections × Sentinel Lymph Node Biopsy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡